News Jaguar Health, Inc.

Stocks

JAGX

US47010C8626

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2026 am IST			5-day change	1st Jan Change
1.335 ^USD	-31.54%		-43.67%	-95.90%

25/06	Jaguar Health, Inc., Napo Pharmaceuticals, Inc., And Woodward Specialty LLC Amend Manufacturing And Supply Agreement	CI
24/06	Jaguar Health Initiates Strategic-Alternatives Review Ahead of Crofelemer NDA Filing for Rare Intestinal Failure Program	CI

All News

Mentions Relevance

30/06	Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)	AQ
25/06	Jaguar Health, Inc., Napo Pharmaceuticals, Inc., And Woodward Specialty LLC Amend Manufacturing And Supply Agreement	CI
25/06	Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend	AQ
24/06	Jaguar Health Initiates Strategic-Alternatives Review Ahead of Crofelemer NDA Filing for Rare Intestinal Failure Program	CI
23/06	Jaguar Health Files New Animal Drug Application For Full FDA Approval Of Canine Diarrhea Therapy	MT
23/06	Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs	AQ
22/06	Jaguar Health Explores Strategic Alternatives	MT
22/06	Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program	AQ
18/06	Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention	AQ
12/06	Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases	AQ
09/06	Jaguar Health, Inc. announced that it expects to receive $41.99992 million in funding	CI
09/06	Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders	AQ
28/05	Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders	AQ
27/05	Jaguar Health Compliant with Nasdaq Bid Price Rule	AQ
26/05	Jaguar Health, Inc., Q1 2026 Earnings Call, May 26, 2026
21/05	Jaguar Health Reports First Quarter 2026 Financials	AQ
21/05	Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
20/05	Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference	AQ
19/05	Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer	AQ
08/05	Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule	AQ
06/05	Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)	AQ
04/05	Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health	AQ
29/04	Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs	AQ
27/04	Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split	AQ
24/04	Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)	AQ